Introduction
============

Major depressive disorder (MDD) is a mental disorder characterized by persistent depressed mood, anhedonia, sleep and appetite disturbances, and feelings of worthlessness, guilt and hopelessness. It is increasingly viewed as an illness of the body as well as of the mind.^[@bib1]^ Both genetic and environmental factors have been associated with the etiology of the disease,^[@bib2]^ but their interplay remains unexplained to date. Stressful life events are associated with the onset and severity of major depression;^[@bib3]^ therefore, we speculated that aberrant adaptive responses to stressors would be also detectable at the cellular level.

Coordination of cellular responses to stress is largely accomplished by mitochondria.^[@bib4]^ Regardless of the type of stress a cell is experiencing (for example, exposure to harmful chemicals, changes of nutrient or oxygen supplies, dangerous levels of reactive oxygen species or even pathogen invasion), mitochondria utilize a wide array of mechanisms aimed at restoring cellular homeostasis.^[@bib5]^ Therefore, the health of these cellular organelles is critical not only for the fate of the individual cells, but for the well-being of the entire organism. Not surprisingly, abnormalities in mitochondrial functions have been implicated in neurological^[@bib6]^ and psychiatric disorders,^[@bib7],\ [@bib8],\ [@bib9]^ and specifically in MDD.^[@bib10]^ In addition, mitochondria are involved in multiple metabolic pathways and are the most prominent generators of energy in the cell. Energy is produced in the cytoplasm through glycolysis, or in the mitochondria through oxidative phosphorylation, also known as mitochondrial respiration. The reliance on energy produced by mitochondrial respiration, rather than glycolysis, can be experimentally shifted by changing the sugar source in the cell culture medium from glucose to galactose (GAL).^[@bib11]^ The shift to oxidative phosphorylation can reveal mitochondrial deficits intersecting control of carbohydrate metabolism and energy homeostasis. Energy production is also tightly interconnected with lipid metabolism through the key metabolite acetyl-CoA. Acetyl-CoA may remain in the mitochondria for energy production or may be exported for *de novo* fatty acid synthesis into the cytoplasm, depending mainly on the availability of fatty acids. This adaptive shift can be experimentally directed by limiting the fatty acid supply in the cell culture medium. Therefore, cellular adaptation to stress can be tested by simple manipulations of the carbohydrate and fatty acids source in the culture medium.

Molecular adaptation to stress in the context of mental disorders is difficult to address in the human brain. Alternatively, we used *in vitro* propagated peripheral cells to test the effects of metabolic stress. Dermal fibroblasts are an appealing cell-based model for studying peripheral events associated with brain disorders, based on the ease of establishing them from skin biopsies, and the ability to maintain in culture without additional reprograming.^[@bib12]^ In addition, the confounding variability in human samples on the basis of patients\' hormones, life style or medication use, are virtually eliminated after several cell divisions. To date, skin fibroblast cultures have been used successfully to elucidate molecular mechanisms associated with schizophrenia^[@bib13],\ [@bib14]^ and developmental disorders,^[@bib15],\ [@bib16]^ and for discerning abnormalities in signal transduction pathways in MDD.^[@bib12],\ [@bib17],\ [@bib18],\ [@bib19]^ In addition, previous reports for dysregulations in lipid metabolism^[@bib20]^ and mitochondrial respiration,^[@bib21]^ suggest abnormalities in mitochondrial function in the periphery of MDD patients. Therefore, we aimed at elucidating whether MDD fibroblasts would in addition exhibit molecular deficits in response to metabolic stressors such as GAL and reduced lipids (RL) in the culture medium. In this manuscript, we present the experimental data gathered from metabolically challenged human dermal fibroblasts and discuss their relevance to MDD.

Materials and methods
=====================

Human fibroblasts
-----------------

This study was approved by the Vanderbilt University Institutional Review Board. Participants were diagnosed with a current major depressive episode according to the Structured Clinical Interview for DSM-IV-TR^[@bib22]^ with an exclusion criteria of other primary axis I DSM-IV diagnosis. Procedures for recruitment and diagnosis have been described previously.^[@bib12],\ [@bib18]^ A written informed consent was obtained from all the participants before any procedures were conducted. Sixteen healthy controls (CNTR) were matched by age, race and gender to MDD patients ([Supplementary Material 1](#sup1){ref-type="supplementary-material"}). The MDD and CNTR subject groups had similar average age (MDD=34.9, CNTR=35.2), representation of gender (12 female and four male) and race (12 white and four African American). Fibroblast cultures were established from skin biopsies according to a protocol previously described.^[@bib12],\ [@bib18]^

Briefly, fibroblast cultures underwent 5--10 passages with DMEM (Dulbecco\'s Modified Eagle\'s medium; Mediatech, Manassas, VA, USA) containing 250 m[M]{.smallcaps} glucose and 1 mM sodium pyruvate, supplemented with 2 m[M]{.smallcaps} L-glutamine (Mediatech), 10% fetal bovine serum (Thermo Scientific HyClone, Logan, UT, USA) and antibiotic/antimycotic solution (Invitrogen, Carlsbad, CA, USA). Cultures were maintained at 37 °C and 5% CO~2~. A cell line from each patient was divided into three plates (plating density 1.2 × 10^6^ cells per plate) and after overnight adherence, each plate received one of the following formulations: (1) standard (STD) medium: DMEM containing 25 m[M]{.smallcaps} glucose; (2) galactose-containing (GAL) medium: DMEM with no glucose, supplemented with 10 m[M]{.smallcaps} GAL (Sigma-Aldrich, St. Louis, MO, USA); (3) RL medium: DMEM containing 25 m[M]{.smallcaps} glucose, supplemented with lipid-reduced fetal bovine serum (Thermo Scientific HyClone). All the cultures were grown for 7 days, refreshing the media every 2 days. The cells were collected after washing with ice-cold phosphate-buffered saline twice, and then trypsinized, pelleted (700 g for 8 min at 18 ºC) and stored at −80 °C until RNA isolation. In all the tested cell lines, neither GAL nor RL exhibited a detectable effect on cell growth and mortality.

RNA isolation and analyses
--------------------------

Total RNA and small RNA fractions were isolated from frozen fibroblasts using mirVana microRNA (miRNA) isolation Kit (Ambion, Austin, TX, USA) according to manufacturer\'s instruction. Both total RNA and small RNA were eluted with 100 μl Elution Solution. Agilent 2100 Bioanalyzer was used to determine the quality and size of the RNA preps. Total RNA integrity number for all messenger RNA (mRNA) samples ranged from 9.4 to 10, and was similar between the MDD and CNTR groups and various conditions. The samples were stored at −80 °C until further use.

The mRNA levels in each fibroblast culture were examined with the GeneChip HT HG-U133+ PM Array Plate (Affymetrix, Santa Clara, CA, USA). The complementary DNA synthesis from total RNA, labeling and hybridization were performed according to manufacturer\'s protocol. The segmented images from each GeneChip were normalized and log2 transformed using GC-robust multi-array analysis.^[@bib23]^ The average logarithmic ratio (ALR=Mean~MDD~−Mean~CNTR~) was calculated for each gene probe, as an indicator for magnitude of change and Student\'s paired and group two-tailed *P*-values as indicators for significance of change. Significance was established according to the dual criteria of \|ALR\|\>0.3785 (30% change) and both pairwise and groupwise *P*⩽0.01. Quantitaive PCR validation of the microarray data was performed with RT^[@bib2]^ custom Profiler PCR Arrays (Qiagen, Valencia, CA, USA), designed to test the mRNA expression level of 10 genes involved in the regulation of lipid metabolism: stearoyl-CoA desaturase (delta-9-desaturase), fatty acid binding protein 3, 7-dehydrocholesterol reductase, insulin induced gene 1, quinolinate phosphoribosyltransferase, 3-hydroxy-3-methylglutaryl-CoA reductase, 3-hydroxy-3-methylglutaryl-CoA synthase 1, low-density lipoprotein receptor, fatty acid desaturase 1, fatty acid desaturase 2. The differentially expressed genes were subjected to a two-way hierarchical clustering analysis using GenePattern software.^[@bib24]^ In addition, for each gene probe, we applied a linear statistical model with gene expression values as the outcome variable and group, stressor and group × stressor as fixed effects (groups: CNTR, MDD; stressors: GAL, RL). Data were analyzed with procedure MIXED in SAS software (version 9.3, SAS Institute, Cary, NC, USA). Gene set enrichment analysis (GSEA) based on pre-defined gene classes were carried out with the GenePattern software.^[@bib25]^ BioCarta defined set of genes were considered significantly overrepresented at *P*⩽0.05.

The miRNA levels were interrogated with miRNome miScript miRNA PCR Arrays (Qiagen). The complementary DNA was prepared from small RNA preps with miScript HiSpec Buffer according to miScript II RT Kit (Qiagen) instructions. The complementary DNA from each sample was quantified and proportionately combined into four pools of samples according to age and gender ([Supplementary Material 1](#sup1){ref-type="supplementary-material"}). Creating multiple sample pools from closely matched individuals allowed us a reduced work load and cost, while still retaining the ability to establish statistical significance in the downstream analyses. However, to avoid any pooling biases and outlier effects, the outcome of these data had to be validated in the individual samples. As a result, significantly changed miRNA levels in each individual fibroblast sample were examined with custom miScript miRNA PCR Arrays. (Qiagen), containing assays for the following miRNAs: miR-146b-5p, miR-550a, miR-214, miR-132\*, miR-376c, miR-19a, miR-181a\*, miR-486-5p, miR-424\*, miR-542-3p, miR-22, miR-376b, miR-29b, miR-564. The selection of the 14 miRNA assays was based on a statistically significant difference in response to GAL or RL in the MDD or the CNTR group. The Ct values for each miRNA from both miRNome and custom qPCR arrays were normalized to the average Ct from a set of housekeeping genes and thus ΔCt values were generated. At Ct \>35, a miRNA level was considered non-detectable. In cases where the levels of a miRNA were non-detectable in two or more samples within a group, the miRNA was not used for further comparisons. The miRNA difference of expression between groups was measured by ΔΔCt~RL~=MeanΔCt~RL~−MeanΔCt~STD~ and ΔΔCt~GAL~=MeanΔCt~GAL~−MeanΔCt~STD~. A miRNA was considered differentially expressed when \|ΔΔCt\|\>0.3785 and pairwise *P*⩽0.05. Group × stressor interaction was determined by the dual criteria of \|ΔΔΔCt\|\>0.3785 (30% difference) and groupwise *P*⩽0.05. ΔΔΔCt~GAL~=ΔΔCt~MDDGAL~−ΔΔCt~CNTRGAL~; ΔΔΔCt~RL~=ΔΔCt~MDDRL~−ΔΔCt~CNTRRL~.

Results
=======

MDD fibroblast response to metabolic stress: mRNA changes
---------------------------------------------------------

Metabolic stress response in MDD and CNTR fibroblasts from 32 subjects (16 MDD and 16 CNTR) was achieved by exposure to culture media containing GAL or RL ([Supplementary Material 2](#sup1){ref-type="supplementary-material"}). Analysis of mRNA species by oligonucleotide microarrays revealed that GAL substitution of glucose in the growth medium resulted in robust changes in the transcriptome of both MDD and CNTR fibroblasts. Using dual criteria for establishing significant expression differences (\|ALR~GAL−STD~\| \> 0.3785 (30% change) and both group- and pairwise *P*⩽0.01), we identified 1196 transcripts changed in GAL-treated MDD fibroblasts ([Supplementary Material 3A](#sup1){ref-type="supplementary-material"}). Of those, 975 were upregulated as a result of GAL treatment. According to the same criteria, 1111 probes were changed in CNTR fibroblasts, 733 of which were upregulated. In comparison with the CNTR fibroblasts, MDD fibroblasts revealed a distinct GAL-induced mRNA pattern; of the total number of mRNAs, 310 (26%) were only exhibited in MDD ([Supplementary Material 4A](#sup1){ref-type="supplementary-material"}).

RL treatment also resulted in pronounced mRNA changes in both MDD and CNTR cells. Differential expression in RL conditions (compared with STD media) was noted for 312 transcripts in the MDD: 262 upregulated and 50 downregulated mRNAs. Similarly, in CNTR fibroblast, 360 mRNA species (261 upregulated, 99 downregulated) were differentially expressed in RL compared with STD conditions ([Supplementary Material 3B](#sup1){ref-type="supplementary-material"}). Importantly, the MDD fibroblasts responded to RL condition differently than CNTR; 103 (33.4%) of all mRNA changes induced by RL were only exhibited in MDD ([Supplementary Material 4B](#sup1){ref-type="supplementary-material"}).

It was remarkable that both GAL and RL treatments resulted in distinct mRNA changes in MDD fibroblasts that were not present in CNTR, therefore, we further sought to identify the interaction effect between disease state and metabolic challenge (group × stressor) by applying a linear statistical model. We used a dual significance cutoff criterion of \|ΔALR\|\>0.3785 (30% change) and *P*⩽0.01. We found that the characteristic MDD signature in response to GAL (MDD × GAL) was defined by 28 ([Figure 1a](#fig1){ref-type="fig"}), and in response to RL (MDD × RL) was defined by 20 mRNA species ([Figure 1b](#fig1){ref-type="fig"}). Two of the genes (integrator complex subunit 4; INTS4 and NEDD4 binding protein 2-like 1; N4BP2L1) overlapped in the MDD × GAL and MDD × RL response-defining pattern.

Custom qPCR arrays were used to validate the microarray-detected mRNA changes in response to GAL and RL. The arrays were designed to test the mRNA expression level of 10 genes involved in lipid metabolism with significantly changed expression in MDD and in CNTR samples in GAL vs STD and in RL vs STD conditions. The statistical significance of the microarray-detected expression changes for all 10 genes was confirmed by qPCR ([Figure 2](#fig2){ref-type="fig"}). In addition, the microarray\'s ALRs had a high correlation with the qPCR\'s −ΔΔCt in both GAL vs STD and RL vs STD comparisons.

To better understand what molecular pathways are differently engaged in MDD compared with CNTR in response to metabolic stress, we performed GSEA with predetermined gene sets by BioCarta. Significantly enriched gene sets, representing molecular pathways, were identified for both MDD and CNTR in GAL and RL environment ([Table 1](#tbl1){ref-type="table"}, GSEA). GAL treatment induced enrichment of 21 pathways in MDD and 17 in CNTR. Nine of the 21 gene sets (43%) were only enriched in MDD and are involved in cell cycle regulation (PTC1, MPR, ACAP95, ARF), apoptosis (HSP27, SET, BAD), anti-inflammation (IL10) and cell survival (IL7). RL resulted in enrichment of 19 pathways in MDD and 15 in CNTR. Ten of the 19 gene sets (53%) were only enriched in MDD and are involved in cell repair (TFF), survival (TRKA), migration (ECM) and proliferation (CDMAC, SPRY), and also in regulation of metabolism (GH) and energy production (FEEDER, GLYCOLYSIS). Overall, GSEA revealed that the specific changes in MDD evoked by both metabolic stressors are represented by approximately half of all detected molecular pathways, indicating that MDD fibroblasts utilize different strategies for adaptation to the metabolic stressors. Moreover, challenging the MDD fibroblasts with GAL and RL exposed characteristic molecular signatures undetectable at STD conditions.

MDD fibroblast response to metabolic stress: miRNA changes
----------------------------------------------------------

The miRNAs are important regulators of mRNA function and they are heavily involved in control of metabolism and energy homeostasis.^[@bib26]^ Therefore, we sought to identify the miRNA response to metabolic challenges in the same MDD fibroblasts in which differential mRNA expression patterns had been established.

The miRNA samples, isolated individually from the 16 MDD and 16 CNTR fibroblast cultures, were pooled into four sets according to the patients\' age and gender ([Supplementary Material 1](#sup1){ref-type="supplementary-material"}). Human miRNome miScript miRNA PCR Arrays (Qiagen) were used to profile the expression of the 1008 most abundantly expressed miRNA species in the human miRNA genome (miRNome). Approximately 50% of the assayed miRNAs were detected in human cultured dermal fibroblasts, regardless of disease status or culture condition. Significant expression differences in metabolic stress vs STD conditions were defined when change was larger than 30% (\|ΔΔCt\|\>0.3785) and paired *t*-test *P*⩽0.05. In response to GAL challenge, MDD fibroblasts revealed expression changes in 63 miRNAs ([Supplementary Material 5A](#sup1){ref-type="supplementary-material"}). The number of miRNAs changed by GAL challenge in CNTR samples was substantially lower, 38 miRNAs. In addition, 81% of the miRNAs changed in GAL were specific for MDD fibroblasts.

RL elicited much stronger miRNA response in MDD (147 miRNAs), compared with CNTR (38 miRNA) ([Supplementary Material 5B](#sup1){ref-type="supplementary-material"}), leading us to believe that MDD fibroblasts are experiencing the RL environment as much more stressful than CNTRs. Furthermore, 90% of the miRNA RL-response pattern was observed only in MDD, but not in CNTR.

Validation of miRNome analyses on pooled samples was performed with custom qPCR array of 14 miRNAs (SABiosciences, Qiagen) on individual samples. The ΔΔCt (ΔΔCt~GAL~=ΔCt~GAL~−ΔCt~STD~, ΔΔCt~RL~=ΔCt~RL~−ΔCt~STD~) from the pooled samples for each miRNA was correlated with the corresponding ΔΔCt from the individual samples ([Figure 3](#fig3){ref-type="fig"}). Both GAL- and RL-induced miRNA response demonstrated high correlation between pooled and individual samples with coefficients of *r*~GAL~=0.920 and *r*~RL~=0.785. In addition, 85% of the miRNA changes in the individual samples were significantly different in the predicted direction (*P*⩽0.05), providing a strong validation for the miRNome data.

In addition, in an attempt to identify the miRNA changes that characterize the specific response of MDD to each metabolic challenge, we used a group × challenge linear statistical model and the dual significance criterion of \|ΔΔΔCt\|\>0.3785 and *P*⩽0.05. Thus, we derived two miRNA signatures: (1) representing MDD × GAL interaction (16 miRNAs) and (2) representing MDD × RL interaction (36 miRNAs, [Figure 4](#fig4){ref-type="fig"}). It is noteworthy that miR-7, miR-382, miR-296-5p and miR-3176 were common for both signatures.

Literature search in PubMed for the roles of the MDD × GAL and MDD × RL signature miRNAs revealed an interesting trend toward extensive miRNA involvement in the regulation of metabolism, cell proliferation, survival and migration ([Table 2](#tbl2){ref-type="table"}). In relation to control of metabolism, we found miRNAs regulating insulin levels and secretion, obesity and starvation in both MDD × GAL (38%) and MDD × RL (37%) panels. In addition, eight miRNAs from the MDD × RL panel: miR-3613-3p, miR-33a, miR-192, miR-26a, miR-34a, miR-370, miR-15b and miR-296-5p, have been described in the literature as regulators of lipid metabolism. With regard to cell proliferation and apoptosis, 56% of the MDD × GAL and 61% of the MDD × RL miRNAs are known controllers of various signaling cascades, out of which 13% (GAL) and 33% (RL) affect or are affected by the tumor suppressor protein p53. As p53 is not only a modulator of apoptosis, but is also involved in regulation of metabolism,^[@bib27]^ some overlap between these categories is expected. Furthermore, 25% (MDD × GAL) and 39% (MDD × RL) of the signature miRNAs are known to regulate cell motility. Interestingly, three of them: miR-34a, miR-34b and miR-199a-3p, are recognized as regulators of the hepatocyte growth factor receptor, c-Met,^[@bib28],\ [@bib29]^ a key controller of cell migration.

Discussion
==========

Our results demonstrate that the metabolic challenges evoked by substitution of glucose with GAL or reducing the abundance of lipids in the growth media of fibroblast cultures result in robust changes of mRNA and miRNA expression. MDD fibroblasts responded to the metabolic stress with alternate expression of 1196 (GAL) and 312 (RL) transcripts. A substantial fraction of these mRNA changes, 26% (GAL) and 33% (RL) were only observed in MDD, but not in CNTR. The specific response of MDD fibroblasts to each challenge was represented by 20 (MDD × GAL) and 28 (MDD × RL) mRNAs with significant group by challenge interaction. The characteristic response of MDD fibroblasts to the metabolic stressors was even more pronounced on the miRNA level; 81% (GAL) and 90% (RL) of the total miRNA changes were only observed in MDD, but not in CNTR. The miRNA signature response of MDD fibroblasts was defined by 16 (MDD × GAL) and 36 (MDD × RL) miRNAs. The stress-induced changes, observed on both mRNA and miRNA level, revealed MDD-associated impairments in molecular pathways involved in the control of metabolism and energy production, cell survival, proliferation and migration. These impairments are likely to be present in all the somatic cells, and therefore are informative of the disease process. In fact, the results are consistent with our previous findings in human postmortem brain tissue, as both studies implicated disturbances in apoptotic molecular pathways.^[@bib30]^ Impairments in any of the detected molecular pathways could be critical for the development and plasticity of the brain and can result in the disease state of MDD.^[@bib31]^ In a previous study, MDD fibroblasts cultured in STD condition revealed deficits in cell proliferation and cell motility.^[@bib32]^ In this study, we demonstrated that molecular pathways involved in the same processes were also impaired in response to metabolic challenges with GAL and RL, and revealed previously unknown disruption of pathways regulating metabolism and energy production. Presenting metabolic challenges was instrumental for defining distinct MDD mRNA and miRNA response signatures that might also contribute to patients\' aberrant responses to life stressors.

GAL and RL treatments elicited common responses in MDD fibroblasts. The commonality was demonstrated on both mRNA and miRNA level. On mRNA level, the overlap between MDD × GAL and MDD × RL signatures was defined by the integrator complex subunit 4 (INTS4), and the NEDD4 binding protein 2-like 1 (N4BP2L1). The INTS4 associates with RNA polymerase II, and therefore potentially has a general effect on regulation of gene transcription and RNA processing.^[@bib33]^ The N4BP2L1 is a paralog of N4BP2 and is likely involved in cell survival.^[@bib34]^ Evidence for MDD impairment in the regulation of cell survival and proliferation streamed from the molecular pathway analyses as well. The HSP27, BAD and ARF molecular pathways were the commonly enriched pathways in MDD during GAL and RL challenges; all of which affect cell survival and proliferation. Furthermore, 38% (GAL) and 17% (RL) of the MDD-enriched gene sets (PTC1, MPR, ACAP95, ARF, HSP27, SET, BAD, IL7, TRKA, CDMAC, SPRY), contribute to the regulation of cell survival and proliferation. On the miRNA level, three of the commonly changed miRNAs are regulators of cell proliferation and apoptosis.^[@bib35],\ [@bib36],\ [@bib37]^ In addition, a striking 56--61% of the miRNAs from the MDD × GAL and MDD × RL signatures have roles in cell cycle and survival regulation. Overall, these data provide an overwhelming support for the aberrant engagement of mechanisms regulating cell proliferation and survival by MDD fibroblasts when exposed to two distinct metabolic challenges. Commonality between GAL- and RL-induced responses in MDD was also detected in their respective miRNA signatures, where at least 38% (GAL) and 37% (RL) of the miRNAs were regulators of metabolism or energy homeostasis, indicating deficiencies in those signaling cascades in MDD as well. In summary, the challenges presented by GAL and RL in MDD fibroblasts affected cellular processes, such as control of cell proliferation and survival, regulation of metabolism and energy production. The molecular machinery for regulation of these processes is located mainly in the mitochondria. Therefore, our data strongly support the disruption of mitochondrial functions in patients with MDD, as previously suggested.^[@bib10]^

The GAL and RL treatment also evoked different responses in MDD fibroblasts. The number of mRNAs with changed expression in GAL was four times the number of mRNAs changed in RL. In contrast, the mRNA signatures characterizing the specific response of MDD to each stress, have similar number of mRNAs (MDD × GAL=28, MDD × RL=20). Therefore, the proportion of the specific mRNAs from the total mRNA changes (GAL=1196, RL=360) is in favor of RL (5.6 vs 2.3%). Consequently, we concluded that RL vs GAL environment more strongly illuminates the molecular deficits of MDD. Furthermore, additional data, obtained from RL treatment, reveal abnormalities in MDD, which were not apparent in GAL. These are the eight miRNAs in the MDD × RL miRNA signature known to control lipid metabolism, pointing toward the possibility of fatty acid metabolism dysregulation in patients with MDD, a phenomenon studied in many different ways during the last couple of decades.^[@bib38],\ [@bib39],\ [@bib40],\ [@bib41],\ [@bib42]^ Another interesting fact revealed only in RL environment is the presence of six hypoxamirs in the MDD × RL miRNA signature. Hypoxamirs have been identified as miRNAs contributing to mitochondrial respiration arrest in a low oxygen environment.^[@bib43]^ In our study, CNTR fibroblasts upregulated six hypoxamirs (let-7b\*, miR-192, miR-26a, miR-98, miR-23a and miR-7)^[@bib44]^ in response to RL, whereas MDD fibroblasts downregulated them. This particular difference in the MDD response compared with CNTR further supports the notion of mitochondrial dysfunction in MDD. The RL challenge was also very informative in uncovering abnormalities in the process of cell migration; 39% of the miRNAs in the MDD × RL miRNA signature were regulators of metastasis. Also, MDD responded to RL with enrichment of ECM (extracellular matrix) pathway and TFF (Trefoil factors initiate mucosal healing) pathway; both important players in the processes of cell migration. The deficit of MDD in cell migration was not as apparent during adaptation to GAL, but was observed in a previous study in STD conditions.^[@bib32]^

An important question is whether the changes we detect in peripheral tissues are relevant to a disease process that takes place primarily in the brain. Genetic factors associated with MDD are likely to be present throughout the entire body and not just be specific to the brain. The adaptive deficits detected in fibroblast cell lines can be linked back to the function of neurons and the brain, with multiple examples found in the mRNA and miRNA challenge-response signatures and in the altered molecular pathways. On mRNA level, such examples are presented by genes important for neurite outgrowth, neurodevelopment and synaptic plasticity: Actin-related protein 2/3 complex, subunit 5 (ARPC5),^[@bib45]^ ArfGAP with coiled-coil, ankyrin repeat and PH domains 2 (ACAP2)^[@bib46]^ and Beta-1,3-glucuronyltransferase 2 (glucuronosyltransferase S, B3GAT2).^[@bib47]^ Multiple important roles in the nervous system are associated with miRNA challenge-response signatures as well. Generally, 31% (GAL) and 47% (RL) of the miRNAs from the miRNA signatures are either regulators of molecular events in the brain or biological markers associated with psychiatric disorders in the periphery. In particular, we identified miRNAs with roles in neurite outgrowth and synapse formation: miR-7,^[@bib48]^ miR-26a,^[@bib49]^ miR-34a,^[@bib50]^ miR-134 (ref. [@bib51]) and miR-132;^[@bib52],\ [@bib53]^ cell cycle progression, apoptosis and specification of neurons: miR-25,^[@bib54]^ miR-34a,^[@bib55]^ miR-497 (ref. [@bib56]) and miR-376a;^[@bib57]^ brain morphogenesis: miR-7,^[@bib58]^ miR-370 (ref. [@bib59]) and myelination in the central nervous system: miR-23a.^[@bib60]^ Furthermore, our study identified miRNAs implicated in the pathological development of schizophrenia, such as miR-132 (ref. [@bib61]) and miR-382;^[@bib62]^ and of Alzheimer\'s, such as miR-98.^[@bib63]^ In addition, several of the miRNAs with aberrant challenge-response in MDD have been described as potential peripheral biomarkers for psychiatric or neurological diseases: miR-564 (ref. [@bib64]) and miR-132 for schizophrenia;^[@bib65]^ hsa-let-7g and miR-15b for Alzheimer\'s;^[@bib66]^ and miR-1285, miR-34a and miR-34b for Huntington\'s disease.^[@bib67]^ This study also identified a number of miRNAs that respond to different stressors in the nervous system: miR-34b, which affects the degree of oxidative stress and survival of dopaminergic neurons;^[@bib68]^ miR-296-5p, which responds to oxidative stress in mouse hippocampal neuronal cultures;^[@bib69]^ miR-199a, which reacts to hypoxia in rat cortical pericytes;^[@bib70]^ and miR-98, which is elevated in the brains of newborn rats experiencing prenatal stress.^[@bib71]^ And last, miR-296-5p, which showed aberrant response to both RL and GAL in MDD fibroblasts, presents a strong connection to MDD; miR-296-5p has been identified as a regulator of inducible I kappa-B kinase,^[@bib72]^ a gene with genetic association with MDD.^[@bib73]^

Taken together, this information gives confidence to the relevance of our observations in fibroblasts to the MDD disease state. This study provides a solid foundation for future experiments with human fibroblasts aimed at deciphering the systemic immune disturbances in MDD. Moreover, our results demonstrate that aberrant responses to stressors are indeed present in the peripheral tissues from MDD patients. These responses intersect multiple cellular processes associated with mitochondria, such as regulation of metabolism and energy production, cell proliferation, survival and motility; therefore, they strongly suggest that the stress-response impairments of MDD patients are most likely based on impaired mitochondrial functions.
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![Disease × stressor interaction mRNA signatures. (**a**) MDD × GAL and (**b**) MDD × RL. The ALR (Mean~RL~−Mean~STD~) of the probes with significant disease × challenge interaction were subjected to unsupervised hierarchical clustering. The colored squares represent the increase (red) or decrease (blue) of each ALR from the mean. Color intensity is proportional to magnitude of change. Clear separation of MDD and CNTR groups was observed. Furthermore, two genes (INTS4 and N4BP2L1---denoted by arrows) are commonly present in both signatures. CNTR, control; GAL, galactose; MDD, major depressive disorder; mRNA, messenger RNA; RL, reduced lipid; STD, standard.](tp201514f1){#fig1}

![qPCR validation of the differential mRNA expression detected with microarrays. The differential expression of 10 mRNAs, detected with microarrays, was validated with custom qPCR arrays (groups: MDD, CNTR; culture conditions: STD, GAL, RL). ALR (ALR~GAL~=Mean~GAL~− Mean~STD~, blue, ALR~RL~=Mean~RL~− Mean~STD~, pink) was used as an estimate for the microarray expression changes and was plotted on the x axis. ΔΔCt (ΔΔCt~GAL~=ΔCt~GAL~−ΔCt~STD~, blue; ΔΔCt~RL~=ΔCt~RL~−ΔCt~STD,~ pink) was used for a qPCR expression changes estimate and was plotted as −ΔΔCt on the y axis. Note that the estimates from both analyses in each comparison were highly correlated. CNTR, control; GAL, galactose; MDD, major depressive disorder; mRNA, messenger RNA; qPCR, quantitative PCR; RL, reduced lipid; STD, standard.](tp201514f2){#fig2}

![Differential miRNA expression in pooled samples is validated in individual samples. The expression level of 14 miRNAs, detected in miRNome analyses of pooled samples, was validated with independent qPCR arrays of individual samples (groups: MDD, CNTR; culture conditions: STD, GAL, RL). The expression changes, estimated with ΔΔCt (ΔΔCt~GAL~=ΔCt~GAL~−ΔCt~STD~, blue; ΔΔCt~RL~=ΔCt~RL~−ΔCt~STD,~ pink), from the pooled samples are plotted on the x axis, and from the individual samples on the y axis. Note that the values from each comparison were highly correlated. CNTR, control; GAL, galactose; MDD, major depressive disorder; miRNA, microRNA; qPCR, quantitative PCR; RL, reduced lipid; STD, standard.](tp201514f3){#fig3}

![Disease × stressor interaction miRNA signatures. (**a**) MDD × GAL and (**b**) MDD × RL. The ΔΔCts (ΔΔCt~GAL~=ΔCt~GAL~−ΔCt~STD~; ΔΔCt~RL~=ΔCt~RL~−ΔCt~STD~) of the miRNAs with significant disease × challenge interaction were subjected to unsupervised hierarchical clustering. The colored squares represent the increase (red) or decrease (blue) of each ΔΔCt from the mean. Increased ΔΔCt represents reduced level of miRNA in metabolic stress compared with STD conditions. Clear separation of MDD and CNTR groups was observed. Four miRNAs (that is, miR-7, miR-382, miR-296-5p and miR-3176), denoted by arrows, are commonly present in both signatures. CNTR, control; GAL, galactose; MDD, major depressive disorder; miRNA, microRNA; RL, reduced lipid; STD, standard.](tp201514f4){#fig4}

###### BioCarta GSEA enrichment of mRNA expression in response to GAL and RL challenges

  *Pathway*                *Size*   *NES*   P*-value*
  ------------------------ -------- ------- -----------
  *Enriched in CNTR GAL*                    
   **RACCYCD**             26       1.89    0.0076
   CELLCYCLE               23       1.81    0.0000
   TEL                     18       1.74    0.0040
   SRCRPTP                 11       1.72    0.0000
   P53                     16       1.66    0.0078
   CERAMIDE                22       1.65    0.0115
   **CFTR**                12       1.62    0.0000
   CHREBP2                 42       1.61    0.0275
   G2                      24       1.61    0.0199
   ATRBRCA                 21       1.58    0.0159
   CARM_ER                 34       1.58    0.0373
   **STATHMIN**            19       1.56    0.0233
   **ATM**                 20       1.55    0.0492
   CHEMICAL                22       1.53    0.0497
   RB                      13       1.53    0.0346
   **AKAPCENTROSOME**      15       1.52    0.0471
   PLCE                    12       1.51    0.0299
                                            
  *Enriched in CNTR RL*                     
   PPARA                   56       1.83    0.0000
   RACCYCD                 26       1.71    0.0229
   CHREBP2                 42       1.65    0.0136
   CD40                    15       1.59    0.0301
   ARF                     17       1.57    0.0359
   **VIP**                 26       1.57    0.0169
   **P38MAPK**             39       1.53    0.0076
   HSP27                   15       1.50    0.0389
   BAD                     26       1.50    0.0217
   **GCR**                 19       1.47    0.0360
   **LYM**                 11       1.43    0.0368
   **PLCE**                12       1.43    0.0443
   **IL22BP**              16       −1.53   0.0300
   DNAFRAGMENT             10       −1.54   0.0237
   AHSP                    11       −1.56   0.0412
                                            
  *Enriched in MDD GAL*                     
   TEL                     18       1.98    0.0000
   SRCRPTP                 11       1.73    0.0020
   **PTC1**                11       1.73    0.0000
   G2                      24       1.66    0.0021
   CARM_ER                 34       1.66    0.0056
   **HSP27**               15       1.65    0.0116
   RB                      13       1.62    0.0062
   CERAMIDE                22       1.60    0.0212
   P53                     16       1.58    0.0220
   **SET**                 11       1.58    0.0328
   CHEMICAL                22       1.58    0.0243
   ATRBRCA                 21       1.57    0.0080
   **MPR**                 34       1.56    0.0413
   CELLCYCLE               23       1.56    0.0305
   **AKAP95**              12       1.56    0.0469
   CHREBP2                 42       1.56    0.0222
   **IL10**                17       1.53    0.0320
   **ARF**                 17       1.50    0.0382
   PLCE                    12       1.47    0.0301
   **IL7**                 17       1.46    0.0258
   **BAD**                 26       1.43    0.0138
                                            
  *Enriched in MDD RL*                      
   RACCYCD                 26       1.90    0.0040
   **TFF**                 21       1.88    0.0064
   CD40                    15       1.78    0.0102
   **TRKA**                12       1.74    0.0084
   **ECM**                 24       1.67    0.0234
   PPARA                   56       1.63    0.0066
   HSP27                   15       1.62    0.0176
   **GH**                  28       1.60    0.0204
   **GLEEVEC**             23       1.58    0.0361
   ARF                     17       1.54    0.0463
   **EXTRINSIC**           13       1.53    0.0140
   CHREBP2                 42       1.53    0.0246
   **CDMAC**               16       1.52    0.0355
   BAD                     26       1.48    0.0118
   **SPRY**                18       1.45    0.0417
   **FEEDER**              9        −1.53   0.0236
   DNAFRAGMENT             10       −1.54   0.0488
   AHSP                    11       −1.56   0.0354
   **GLYCOLYSIS**          10       −1.63   0.0040

Abbreviations: CNTR, control; GAL, galactose; GSEA, gene set enrichment analysis; MDD, major depressive disorder; mRNA, messenger RNA; RL, reduced lipid.

Molecular pathway enrichment of mRNA in MDD and CNTR. Pathways enriched only in one group (MDD or CNTR) are in bold.

###### Experimentally established involvement of the miRNAs from MDD × GAL and MDD × RL signatures in cellular processes (on the basis of PubMed search)

  *Physiological process*   *miRNA_ID*
  ------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *MDD × GAL miRNA*         
  Metabolism                miR-33a\*, miR-7, miR-296-5p, miR-181a\*, miR-497\*
  Fatty acid metabolism     miR-296-5p, miR-193a-3p ×
  P53                       miR-1208, miR-1285, miR-7
  Apoptosis/proliferation   miR-548c-5p, miR-7, miR-382, miR-296-5p, miR-181\*, miR-193a-3p, miR-1285, miR-32, miR-497\*
  Migration/c-MET           miR-548c-5p, miR-7, miR-296-5p, miR-497\*
  Neurons/psychiatry        miR-7, miR-382, miR-296-5p, miR-32, miR-497\*
                             
  *MDD × RL miRNA*          
  Metabolism                miR-33a, miR-7, miR-661, miR-1307, miR-376a, miR-26a, miR-132, miR-25, miR-98, miR-34a, miR-23a, miR-199a/b-3p, miR-296-5p
  Fatty acid metabolism     miR-3613-3p, miR-33a, miR-192, miR-26a, miR-34a, miR-370, miR-15b, miR-296-5p
  P53                       miR-34b, miR-16-1\*, miR-661, miR-192, miR-7, miR-134, miR-25, miR-98, miR-34a, miR-370, miR-15b, miR-199a/b-3p
  Apoptosis/proliferation   miR-33a, miR-34b, miR-16-1\*, miR-661, miR-192, miR-7, miR-376a, miR-382, miR-26a, miR-134, miR-379, let-7g, miR-132, miR-25, miR-98, miR-34a, miR-370, miR-15b, miR-23a, miR-199a/b-3p, miR-100, miR-296-5p
  Migration/c-MET           miR-34b, miR-661, miR-550a, miR-7, miR-376a, miR-26a, let-7g, miR-134, miR-132, miR-25,miR-98, miR-34a, miR-100, miR-296-5p
  Neurons/psychiatry        miR-34b, miR-7, miR-376a, miR-382, miR-26a, miR-134, miR-564, let-7g, miR-132, miR-25, miR-98, miR-34a, miR-370, miR-15b, miR-23a, miR-199a/b-3p, miR-296-5p

Abbreviations: GAL, galactose; MDD, major depressive disorder; miRNA, microRNA; RL, reduced lipid.

Metabolism/fatty acid metabolism.^[@bib36],\ [@bib63],\ [@bib74],\ [@bib75],\ [@bib76],\ [@bib77],\ [@bib78],\ [@bib79],\ [@bib80],\ [@bib81],\ [@bib82],\ [@bib83],\ [@bib84],\ [@bib85],\ [@bib86],\ [@bib87],\ [@bib88],\ [@bib89],\ [@bib90],\ [@bib91],\ [@bib92],\ [@bib93],\ [@bib94]^ Apoptosis/proliferation/p53.^[@bib37],\ [@bib49],\ [@bib54],\ [@bib56],\ [@bib58],\ [@bib95],\ [@bib96],\ [@bib97],\ [@bib98],\ [@bib99],\ [@bib100],\ [@bib101],\ [@bib102],\ [@bib103],\ [@bib104],\ [@bib105],\ [@bib106],\ [@bib107],\ [@bib108],\ [@bib109],\ [@bib110],\ [@bib111],\ [@bib112],\ [@bib113],\ [@bib114],\ [@bib115],\ [@bib116],\ [@bib117],\ [@bib118]^Migration.^[@bib29],\ [@bib54],\ [@bib98],\ [@bib99],\ [@bib119],\ [@bib120],\ [@bib121],\ [@bib122],\ [@bib123],\ [@bib124],\ [@bib125],\ [@bib126],\ [@bib127],\ [@bib128],\ [@bib129],\ [@bib130],\ [@bib131]^ Neurons/psychiatry.^[@bib48],\ [@bib49],\ [@bib50],\ [@bib51],\ [@bib53],\ [@bib54],\ [@bib56],\ [@bib57],\ [@bib58],\ [@bib60],\ [@bib61],\ [@bib63],\ [@bib64],\ [@bib65],\ [@bib66],\ [@bib68],\ [@bib69],\ [@bib70],\ [@bib71],\ [@bib98],\ [@bib132],\ [@bib133],\ [@bib134]^
